Grown Rogue International (GRUSF) Restructuring Costs (2019 - 2020)
Grown Rogue International (GRUSF) posted quarterly Restructuring Costs of $8882.0 for Q3 2020, down 81.79% year-over-year from $48777.0 in Q3 2019, and down 25.79% quarter-over-quarter from $11969.0 in Q2 2020.
Grown Rogue International (GRUSF) Restructuring Costs (2019 - 2020) Analysis & Trends
Grown Rogue International's Restructuring Costs history runs 2 years deep, the most recent figure standing at $8882.0 for Q3 2020.
- In Q3 2020, Restructuring Costs fell 81.79% year-over-year to $8882.0; the TTM figure through Jul 2020 stood at -$236811.0 (changed N/A YoY), while the FY2019 annual figure was $3.5 million, up 9353.37% from the prior year.
- Restructuring Costs for Q3 2020 stood at $8882.0, down from $11969.0 in the prior quarter.
- The five-year high for Restructuring Costs was $3.7 million in Q1 2019, with the low at -$269934.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - |
| 10 | Grown Rogue International | 110.47 Mn | 98.93 Mn | 5.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2020 | 8,882.00 |
| Apr 30, 2020 | 11,969.00 |
| Jan 31, 2020 | 12,272.00 |
| Oct 31, 2019 | -269,934.00 |
| Jul 31, 2019 | 48,777.00 |
| Apr 30, 2019 | 9,347.00 |
| Jan 31, 2019 | 3.72 Mn |